AiCure

Articles Published in 2012

Elan completes demerger of Prothena

Friday, December 21, 2012 02:40 PM

Dublin-based Elan has completed the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena. Incorporated in Ireland, Prothena commenced trading on the NASDAQ Global Market as of Dec. 21.

More... »


Synteract to acquire Harrison Clinical Research

Thursday, December 20, 2012 10:37 AM

CRO Synteract, a portfolio company of San Francisco-based Gryphon Investors, has agreed to acquire Harrison Clinical Research (HCR).

More... »


WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

Merck, GE Healthcare collaborate on imaging biomarkers for BACE inhibitor program

Wednesday, December 19, 2012 01:18 PM

Merck and GE Healthcare have formed a clinical study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

More... »

Texas Health Resources selects Daniel Varga as CCO

Wednesday, December 19, 2012 12:08 PM

Texas Health Resources, a faith-based, nonprofit health system, has selected Daniel Varga, M.D., as its chief clinical officer (CCO) and senior executive vice president of the health system, effective Jan. 14.

More... »

Stansfield joins PharmaNet/i3 as executive vice president, clinical operations

Wednesday, December 19, 2012 11:39 AM

PharmaNet/i3, inVentiv Health’s clinical segment and a provider of clinical development services, has appointed Dr. Susan C. Stansfield as executive vice president of clinical operations for phase II-IV development in Europe, Middle East and Africa (EMEA), Asia-Pacific and Latin America. 

More... »

Oncodesign, KU Leuven, Ipsen collaborate on advancing drug discovery in Parkinson's disease

Wednesday, December 19, 2012 11:11 AM

Oncodesign, a biotech based in France, and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Katholieke Universiteit Leuven, have entered into a research collaboration to evaluate, along with a global specialty-driven pharmaceutical company Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease.

More... »

New company NeRRe Therapeutics created to develop neurokinin antagonists from GSK

Wednesday, December 19, 2012 10:42 AM

NeRRe Therapeutics, a new drug discovery company, has been launched to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (GSK).

More... »

Regado Biosciences secures $51M Series E financing

Wednesday, December 19, 2012 10:13 AM

Regado Biosciences, a Basking Ridge, N.J.-based private biopharmaceutical company developing antithrombotic aptamers with active control agents, has secured a landmark $51 million Series E financing. 

More... »

Arrowhead, Shire ink agreement to develop peptide-targeted therapeutics

Wednesday, December 19, 2012 09:41 AM

Arrowhead Research, a clinical stage targeted therapeutics company, has signed a research collaboration and license agreement with Shire, a specialty biopharmaceutical company, to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs